Seladelpar lysine is a Small Molecule owned by CymaBay Therapeutics, and is involved in 12 clinical trials, of which 9 were completed, and 3 are ongoing.

Seladelpar lysine (MBX-8025, RWJ-800025) is a peroxisomal proliferator-activated receptor delta (PPAR-delta) agonist. It is a nuclear transcription factor that regulates genes involved in lipid storage and transport (particularly in fatty acid oxidation) and insulin signaling and sensitivity. PPARs regulates the expression of genes that affect blood lipid metabolism, the generation of adipocytes (fat cells), and blood glucose control. PPAR-delta is produced in virtually all of the cells throughout the body and may have roles in energy metabolism and reducing inflammation.

The revenue for Seladelpar lysine is expected to reach a total of $4.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Seladelpar lysine NPV Report.

Seladelpar lysine was originated by Johnson & Johnson and is currently owned by CymaBay Therapeutics.

Seladelpar lysine Overview

Seladelpar lysine (MBX-8025, RWJ-800025) is under development for the treatment of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC). The drug candidate is administered through the oral route as a capsule. MBX-8025 targets human PPAR-delta receptor. It was under development for the treatment of Fredrickson types I and V hyperlipoproteinemias, non-alcoholic steatohepatitis (NASH), mixed dyslipidemia, severe hypertriglyceridemia (SHTG) and homozygous familial hypercholesterolemia (HoFH).

CymaBay Therapeutics Overview

CymaBay Therapeutics (CymaBay), formerly Metabolex is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, liver and other chronic diseases, orphan diseases, and related metabolic disorders. The company’s pipeline products comprise Seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd) for the treatment of liver diseases. It also develops MBX-2982 for patients with type 1 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical companies and others to develop its product candidates. CymaBay is headquartered in Newark, California, the US.

The operating loss of the company was US$87.6 million in FY2021, compared to an operating loss of US$52.6 million in FY2020. The net loss of the company was US$90 million in FY2021, compared to a net loss of US$51 million in FY2020.

Quick View – Seladelpar lysine

Report Segments
  • Innovator
Drug Name
  • Seladelpar lysine
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.